Impact of Adjuvant Radiotherapy and Mitotane on Survival in Localized Adrenocortical Carcinoma: A Retrospective Cohort Study
International Journal of Urology · 2026
DOI: 10.1111/iju.70319 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift International Journal of Urology, 2026. Verfasst von Aysenur Elmali und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Baskent University Faculty of Medicine, Ankara, Turkiye. Hauptthemen laut MEDLINE: Adrenocortical Carcinoma, Mitotane, Adrenal Cortex Neoplasms, Antineoplastic Agents, Hormonal. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben.
Abstract (Originalsprache)
Objectives
Adrenocortical carcinoma (ACC) is a rare, aggressive tumor with high recurrence rates after surgery. Although radiotherapy (RT) has historically been underutilized in ACC, modern RT techniques have renewed interest in its potential role for improving local control (LC). This study evaluated long‐term outcomes and prognostic factors in high‐risk localized ACC treated with adjuvant RT and mitotane.
Methods
In this multicenter retrospective study, 23 patients with localized, high‐risk ACC who underwent complete surgical resection followed by adjuvant RT between 2003 and 2023 were analyzed. All received mitotane, and 21.6% also received platinum‐based chemotherapy. RT was delivered using image‐guided IMRT or VMAT to a median dose of 50.4 Gy, targeting the tumor bed with or without regional lymphatics. Survival was estimated using the Kaplan–Meier method, and prognostic factors were assessed with Cox regression analyses.
Results
At a median follow‐up of 84.7 months, the 5‐year LC, overall survival (OS), and disease‐free survival (DFS) rates were 85.5%, 58.6%, and 45.6%. Locoregional recurrence occurred in two patients (8.6%), with isolated local failure in one (4.3%). Distant metastasis (DM) developed in 47.8% and was the predominant failure pattern. On univariable analysis, age > 55 years predicted worse OS and DFS, while female sex independently predicted inferior DFS. Treatment was well tolerated, with no grade ≥ 3 RT‐related toxicities.
Conclusions
Adjuvant RT achieves excellent LC with minimal toxicity in high‐risk localized ACC. These exploratory findings, limited by small cohort size, retrospective design, and absence of a comparator group, warrant confirmation in larger prospective multicenter studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, Baskent University Faculty of Medicine, Ankara, Turkiye.
- Department of Radiation Oncology, Baskent University Faculty of Medicine, Adana Dr Turgut Noyan Research and Treatment Center, Adana, Turkiye.
- Department of Radiation Oncology, Hacettepe University Faculty of Medicine, Ankara, Turkiye.
ORCID-Profile: Pervin Hurmuz, Cem Onal
Zitieren
APA
Elmali, A., Guler, O. C., Ozyigit, G., Hurmuz, P., & Onal, C. (2026). Impact of Adjuvant Radiotherapy and Mitotane on Survival in Localized Adrenocortical Carcinoma: A Retrospective Cohort Study. International Journal of Urology. https://doi.org/10.1111/iju.70319
Vancouver
Elmali A, Guler OC, Ozyigit G, Hurmuz P, Onal C. Impact of Adjuvant Radiotherapy and Mitotane on Survival in Localized Adrenocortical Carcinoma: A Retrospective Cohort Study. International Journal of Urology. 2026. doi:10.1111/iju.70319
BibTeX
@article{Elmali2026,
author = {Elmali, Aysenur and Guler, Ozan Cem and Ozyigit, Gokhan and Hurmuz, Pervin and Onal, Cem},
title = {Impact of Adjuvant Radiotherapy and Mitotane on Survival in Localized Adrenocortical Carcinoma: A Retrospective Cohort Study},
journal = {International Journal of Urology},
year = {2026},
doi = {10.1111/iju.70319}
}
EUVIMED